Hypera Pharma Sustainability Profile
Hypera Pharma, a leading player in the Brazilian pharmaceutical industry, is headquartered in São Paulo, Brazil. Founded in 2010, the company has rapidly established itself as a key provider of prescription and over-the-counter medications, focusing on therapeutic areas such as central nervous system disorders, dermatology, and consumer health. With a diverse portfolio of well-known brands, Hypera Pharma distinguishes itself through its commitment to innovation and quality, ensuring that its products meet the highest standards. The company has achieved significant market presence, becoming one of the largest pharmaceutical companies in Brazil, and has garnered recognition for its strategic acquisitions and robust growth trajectory. Hypera Pharma continues to enhance its position in the industry by prioritising research and development, aiming to improve health outcomes for patients across the region.
DitchCarbon Score
How does Hypera Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Hypera Pharma's score of 30 is higher than 50% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Hypera Pharma's reported carbon emissions
In 2024, Hypera Pharma reported total carbon emissions of approximately 50,168,760 kg CO2e in Brazil. This figure reflects the company's ongoing commitment to reducing its carbon footprint. Notably, Hypera Pharma has set ambitious targets to reduce its Scope 1 and Scope 2 greenhouse gas emissions by 42% by 2030, using 2020 as the baseline year. This target has been validated by the Science Based Targets initiative (SBTi) and is aligned with the goal of limiting global warming to 1.5°C. The company has demonstrated a commitment to improving its emissions intensity, achieving a reduction of about 2.6% in Scope 1 emissions intensity per unit of revenue in recent years. However, specific data on Scope 3 emissions remains undisclosed, although Hypera Pharma is actively working to measure and reduce these emissions as part of its climate strategy. Overall, Hypera Pharma's climate commitments reflect a proactive approach to sustainability, with a focus on significant reductions in greenhouse gas emissions across its operations.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | |
|---|---|---|
| Scope 1 | 23,726,750 | 00,000,000 |
| Scope 2 | 3,852,990 | 0,000,000 |
| Scope 3 | 17,223,730 | 00,000,000 |
How Carbon Intensive is Hypera Pharma's Industry?
How Carbon Intensive is Hypera Pharma's Location?
Hypera Pharma's Scope 3 Categories Breakdown
Hypera Pharma's Scope 3 emissions, which decreased by 6% last year and decreased by approximately 6% since 2020, demonstrating supply chain emissions tracking. A significant portion of their carbon footprint comes from suppliers and value chain emissions, with Scope 3 emissions accounting for 32% of total emissions under the GHG Protocol, with "Employee Commuting" being the largest emissions source at 13% of Scope 3 emissions.
Top Scope 3 Categories
Hypera Pharma's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Hypera Pharma has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Adium Pharma S.A.
Laboratorios Bago De Bolivia S.A.
Frequently Asked Questions
Common questions about Hypera Pharma's sustainability data and climate commitments